Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Delayed Quote USD

Bright Minds Biosciences Inc. (DRUG)

Compare
33.11
+1.10
+(3.44%)
At close: April 17 at 4:00:02 PM EDT
33.06
-0.05
(-0.15%)
After hours: April 17 at 6:36:03 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for DRUG

Recent News: DRUG

View More
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
GlobeNewswire last month
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
GlobeNewswire last month
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire 3 months ago
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
GlobeNewswire 4 months ago
Bright Minds Biosciences Secures $35 Million Investment

Bright Minds Biosciences Secures $35 Million Investment
TipRanks 5 months ago
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
GlobeNewswire 5 months ago
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
GlobeNewswire 5 months ago
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
GlobeNewswire 5 months ago
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
GlobeNewswire 5 months ago
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
GlobeNewswire 5 months ago
Bright Minds is Unaware of Any Material Changes

Bright Minds is Unaware of Any Material Changes
Newsfile 5 months ago
View More

Related Tickers

TPST Tempest Therapeutics, Inc.
7.28
+0.41%
 
VRAX Virax Biolabs Group Limited
0.9935
-3.54%
 
ENSC Ensysce Biosciences, Inc.
1.7600
-6.38%
 
DWTX Dogwood Therapeutics, Inc.
4.2700
+14.48%
 
ALLR Allarity Therapeutics, Inc.
0.9400
+17.93%
 
CDT Conduit Pharmaceuticals Inc.
0.6201
-20.51%
 
GNPX Genprex, Inc.
0.2400
-6.07%
 
CADL Candel Therapeutics, Inc.
4.5700
+0.88%
 
TVGN Tevogen Bio Holdings Inc.
0.9796
-3.96%
 
MTVA MetaVia Inc.
0.7390
+0.91%